BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 19, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/16 cls
Anesiva (NASDAQ:ANSV) Fortis Patrick Moriarty Price target Buy -16% $0.64
Moriarty raised his target to $1.50 from $0.75 after FDA approved an sNDA for Zingo to treat pain associated with blood draws in adults. He said the label expansion adds "some value" as the company looks to out-license commercial rights to the needle-free injection of lidocaine powder. Last year, Anesiva announced it would discontinue commercial activities and seek a partner for Zingo, which also is approved to treat pain associated with peripheral IV insertions and blood draws in children. It cited continued manufacturing problems, including stability issues (see BioCentury, Nov. 17, 2008). Moriarty said the company is an "interesting acquisition candidate."
Celgene (NASDAQ:CELG) Lazard Matthew Osborne ...

Read the full 823 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >